Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.075 USD | +0.49% | -3.46% | +51.98% |
May. 10 | Leerink Partners Starts Aquestive Therapeutics With Outperform Rating, $8 Price Target | MT |
May. 08 | Transcript : Aquestive Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+51.98% | 279M | |
+37.66% | 727B | |
-7.87% | 354B | |
+15.67% | 328B | |
-0.23% | 277B | |
+13.47% | 243B | |
+7.35% | 205B | |
-6.42% | 203B | |
+3.88% | 164B | |
-2.10% | 164B |
- Stock Market
- Equities
- AQST Stock
- News Aquestive Therapeutics, Inc.
- Aquestive Therapeutics Obtains FDA Approval for Libervant to Treat Seizure in Children